1
ALL1
Porton BiopharmaYear
1
ALL1
2020DEALS // DEV.
1
ALL1
DealsCountry
1
ALL1
UNITED KINGDOM1
ALL1
Clinigen GroupTherapeutic Area
1
ALL1
OncologyStudy Phase
1
ALL1
ApprovedDeal Type
1
ALL1
Licensing AgreementProduct Type
1
ALL1
Large moleculeDosage Form
1
ALL1
Lyophilized SolutionLead Product
1
ALL1
AsparaginaseTarget
0
ALLLead Product(s) : Asparaginase
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Clinigen Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Porton Biopharma Limited Licenses Erwinase® to Clinigen
Details : Under the terms of the agreement, Clinigen will distribute Erwinase®/ Erwinaze®, the Porton's life-saving treatment for acute lymphoblastic leukaemia.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 16, 2020
Lead Product(s) : Asparaginase
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Clinigen Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?